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Introduction
• What is SBRT?
• SBRT is a form of external beam radiation
therapy that provides noninvasive cancer
treatment (Wei et al., 2022).
• “SBRT delivers a hypofractionated dose to
the target volume while sparing surrounding
tissue” (Kessel et al., 2020, p. 2).
• SBRT is well known for achieving excellent
local tumor control (Kennedy et al., 2019).

• Lung cancer information
• More than half of all cancer patients
experience lung metastases (Kessel et al.,
2020).
• SBRT may not be a favorable choice for all
lung cancers. Tumors located within close
proximity to important structures such as the
main bronchus can lead to high-grade
toxicity reactions (Lindberg et al., 2021).

• Why use SBRT for treatment of
lung cancer?
• “In cases where surgery cannot be
performed due to the irresectability of the
tumor, insufficient medical patient conditions,
or patient refusal, stereotactic body radiation
therapy (SBRT) reveals a noninvasive
alternative treatment” (Kessel et al., 2020, p.
2).
• With high rates of local tumor control and
minimal toxicity, SBRT provides a promising
cancer treatment option to lung cancer
patients (Wei et al., 2022).

VMAT VS. IMRT
•

SBRT of Lung Metastases

• Background

Volumetric modulated arc therapy
(VMAT)

• 10-15% of early-stage non-small cell lung
cancer cases treated with SBRT result in
local recurrence.

• Irradiates cancerous tumor from many
incident angles, which may cause an
increase in unnecessary dose to the lung
outside of the treatment volume

• “Even in initially operable patients treated
with upfront SBRT, only approximately 20%
of patients with a local recurrence undergo
salvage lung resection. Therefore, for the
majority of patients, radiotherapy remains
the only definitive salvage option in this
setting” (p. 233).

• Treatment delivery times are 70% less
than those of IMRT treatments.
• Weakened conformity in comparison to
intensity modulated radiation therapy (IMRT)
and increased dose delivery accuracy
• Intensity modulated radiation

therapy (IMRT)
• IMRT treatments report higher doses to the
spinal cord, skin, and esophagus than VMAT
treatments.
• Flatter dose fall-off curve than that of
VMAT treatment
• Better homogeneity and increased
pulmonary toxicity

• Similarities
• Doses to the ribs do not demonstrate
mentionable difference between VMAT and
IMRT treatment types.
• Dose fall-off trends become very similar
between both treatment types as the
distance from the primary treatment volume
(PTV) increases.
• No difference in PTV conformity from
VMAT to IMRT (Wei et al., 2022)

Pre and post SBRT cross sectional lung images for comparison. (Trifletti et al.,
2019, p. 605)

• Outcomes
• Patients who did not receive chemotherapy
but received higher dose SBRT lived longer.

• Of the participants, 67% initially. received
54 Gy in 3 fractions and 33% initially
received 50 Gy in 5 fractions.

• 69.9% of patients with lung metastases
treated with SBRT passed away in the study
conducted between 2004 and 2019.

• For salvage SBRT, 57% of participants
received 50 Gy in 5 fractions and 43%
received 54 Gy in 3 fractions.

• The overall survival rate was found to have
a median of 27.6 months.

• Toxicity of salvage SRT

• Severe dyspnea was a common complaint
of patients post-SBRT.
• Dyspnea was linked to chronic obstructive
pulmonary disease (COPD) as all patients
who reported it were also diagnosed with
COPD prior to treatment.

• No toxicity above grade 3 was reported in
this study and no toxicity of the esophagus
or bronchial tree reported.
• Grade 2 radiation pneumonitis was
reported by 2 participants.

• Toxicity

• Four participants reported chest wall
toxicity, two of these reports were rib
fractures.

• Most documented toxicity is below stage 3.

• Success of salvage SBRT

• “Acute symptomatic pneumonitis grade 2
was observed in 9.7% (20/207), as grade 3
in 0.5% (1/207)” (p. 1).

• In a group of 21 salvage SBRT patients,
median survival rate was 39 months.

(Kessel et al., 2020)
The treatment area with isodose lines that are color-coordinated according to the
dose of the area. (Trifletti, Chao, Sahgal, & Sheehan, 2019, p. 610)

• Study
• Median age of study participants is 75.

• 6.2% of patients experienced late
pneumonitis.

• SBRT has shorter treatment times and
improved survival rates in lung cancer
patients as opposed to conventionally
fractionated radiation therapy (Kennedy et
al., 2020).

Repeat SBRT Treatment

• Post-salvage estimated primary tumor
control success rate was 80%.
• Post-salvage estimated regional node
control was 89%.
• Post-salvage overall survival rate was 68%.

(Kennedy et al., 2020, p. 232)
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